0001209191-23-016391.txt : 20230306 0001209191-23-016391.hdr.sgml : 20230306 20230306170759 ACCESSION NUMBER: 0001209191-23-016391 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230224 FILED AS OF DATE: 20230306 DATE AS OF CHANGE: 20230306 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Fontenot Jason D. CENTRAL INDEX KEY: 0001851761 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-30171 FILM NUMBER: 23709821 MAIL ADDRESS: STREET 1: 7000 MARINA BLVD CITY: BRISBANE STATE: CA ZIP: 94005 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: SANGAMO THERAPEUTICS, INC CENTRAL INDEX KEY: 0001001233 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 680359556 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 7000 MARINA BLVD CITY: BRISBANE STATE: CA ZIP: 94005 BUSINESS PHONE: 5109706000 MAIL ADDRESS: STREET 1: 7000 MARINA BLVD CITY: BRISBANE STATE: CA ZIP: 94005 FORMER COMPANY: FORMER CONFORMED NAME: SANGAMO BIOSCIENCES INC DATE OF NAME CHANGE: 20000208 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2023-02-24 0 0001001233 SANGAMO THERAPEUTICS, INC SGMO 0001851761 Fontenot Jason D. C/O SANGAMO THERAPEUTICS, INC. 7000 MARINA BLVD. BRISBANE CA 94005 0 1 0 0 SVP, Chief Scientific Officer Common Stock 2023-02-24 4 A 0 42750 0.00 A 145917 D Common Stock 2023-02-25 4 F 0 6559 2.66 D 139358 D Stock Option (Right to Buy) 2.66 2023-02-24 4 A 0 199500 0.00 A 2033-02-23 Common Stock 199500 199500 D Represents shares of common stock issuable upon settlement of a restricted stock unit ("RSU") grant that will vest as to one-quarter (1/4) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP")) through each such date and subject to acceleration as provided in the 2018 EIP. Represents shares underlying the portions of RSU grants that vested on February 25, 2023, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on February 24, 2023 of $2.66/share, pursuant to the terms of the 2018 EIP. This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise. Includes: (a) 6,306 shares resulting from the February 25, 2023 final vesting installment of the Reporting Person's February 25, 2020 RSU grant, (b) 5,548 shares resulting from the February 25, 2023 vesting installment of the Reporting Person's February 25, 2021 RSU grant and 7,344 shares subject to such RSU grant that will vest in one final installment on February 25, 2024, and (c) 8,530 shares resulting from the February 25, 2023 vesting installment of the Reporting Person's February 25, 2022 RSU grant, and the remaining 33,825 shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. One-quarter (1/4) of the shares subject to the option will vest and become exercisable on the first anniversary of the grant date, and the remainder of the shares will vest and become exercisable in 24 successive equal monthly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Jason D. Fontenot, by /s/ Ron A. Metzger, Attorney-in-Fact 2023-03-06